Phreesia (0A23) Share Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0A23 Analyst Ratings

Moderate Buy

2 Buy

3 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Phreesia

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0A23 Stock 12 Month Forecast

Average Price Target

$13.50

▼(-52.63% Downside)

Based on 5 Wall Street analysts offering 12 month price targets for Phreesia in the last 3 months. The average price target is $13.50 with a high forecast of $16.00 and a low forecast of $10.00. The average price target represents a -52.63% change from the last price of $28.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","14":"$14","19":"$19","24":"$24","29":"$29"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,14,19,24,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.5,27.53846153846154,26.576923076923077,25.615384615384617,24.653846153846153,23.692307692307693,22.73076923076923,21.76923076923077,20.807692307692307,19.846153846153847,18.884615384615387,17.923076923076923,16.96153846153846,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.5,27.346153846153847,26.192307692307693,25.03846153846154,23.884615384615387,22.730769230769234,21.576923076923077,20.423076923076923,19.26923076923077,18.115384615384617,16.961538461538463,15.807692307692308,14.653846153846155,{"y":13.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.5,27.076923076923077,25.653846153846153,24.23076923076923,22.807692307692307,21.384615384615383,19.96153846153846,18.53846153846154,17.115384615384613,15.692307692307692,14.269230769230768,12.846153846153845,11.423076923076923,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.5,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.5,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$16.00

Average Price Target$13.50

Lowest Price Target$10.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Richard Close

Canaccord Genuity

$16

Buy

-43.86%

Downside

Reiterated

08/11/26

Phreesia (PHR) Gets a Buy from Canaccord Genuity

Alexei Gogolev

J.P. Morgan

$14

Hold

-50.88%

Downside

Reiterated

06/25/26

Analysts Offer Insights on Healthcare Companies: Owlet (NYSE: OWLT), Phreesia (NYSE: PHR) and TriSalus Life Sciences (NASDAQ: TLSI)

Sean Dodge

BMO Capital

$14

Buy

-50.88%

Downside

Reiterated

06/22/26

Analysts Conflicted on These Healthcare Names: Phreesia (NYSE: PHR) and Novo Nordisk (NYSE: NVO)

Glen Santangelo

Barclays

$10

Hold

-64.91%

Downside

Reiterated

06/15/26

Barclays Sticks to Their Hold Rating for Phreesia (PHR)

Jailendra Singh

Truist Financial

―

Hold

―

Reiterated

06/12/26

Analysts Offer Insights on Healthcare Companies: Aethlon Medical (NASDAQ: AEMD), Johnson & Johnson (NYSE: JNJ) and Phreesia (NYSE: PHR)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$20

Buy

-29.82%

Downside

Reiterated

05/28/26

Jefferies Reaffirms Their Buy Rating on Phreesia (PHR)

Clark Wright

D.A. Davidson

$14

Buy

-50.88%

Downside

Reiterated

05/28/26

Analysts Offer Insights on Healthcare Companies: Phreesia (NYSE: PHR), M3 (Other OTC: MTHRF) and Eisai Co (Other OTC: ESALF)

Ryan Daniels

William Blair

―

Buy

―

Reiterated

05/28/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Phreesia (NYSE: PHR), Agilent (NYSE: A) and Pfizer (NYSE: PFE)

Daniel Grosslight

Citi

$10→$12

Hold

-57.89%

Downside

Reiterated

05/28/26

Phreesia price target raised to $12 from $10 at CitiPhreesia price target raised to $12 from $10 at Citi

Stan Berenshteyn

Wells Fargo

Hold

-68.42%

Downside

Reiterated

05/28/26

Analysts Offer Insights on Healthcare Companies: Phreesia (NYSE: PHR), McKesson (NYSE: MCK) and Biohaven Ltd. (NYSE: BHVN)

Jessica Tassan

Piper Sandler

$23→$12

Hold

-57.89%

Downside

Downgraded

05/28/26

Phreesia downgraded to Neutral from Overweight at Piper SandlerPhreesia downgraded to Neutral from Overweight at Piper Sandler

Ryan MacDonald

Needham

$14

Buy

-50.88%

Downside

Reiterated

05/28/26

Analysts Are Bullish on Top Healthcare Stocks: Phreesia (PHR), CSPC Pharmaceutical Group (CHJTF)

Ryan Halsted

RBC Capital

$19

Buy

-33.33%

Downside

Reiterated

05/27/26

RBC Capital Remains a Buy on Phreesia (PHR)

Scott Schoenhaus

KeyBanc

$15→$12

Buy

-57.89%

Downside

Assigned

04/13/26

Phreesia (PHR) Gets a Buy from KeyBanc

Aaron Kimson

Citizens JMP

―

Hold

―

Downgraded

04/01/26

Phreesia downgraded to Market Perform from Outperform at CitizensPhreesia downgraded to Market Perform from Outperform at Citizens

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Richard Close

Canaccord Genuity

$16

Buy

-43.86%

Downside

Reiterated

08/11/26

Phreesia (PHR) Gets a Buy from Canaccord Genuity

Alexei Gogolev

J.P. Morgan

$14

Hold

-50.88%

Downside

Reiterated

06/25/26

Analysts Offer Insights on Healthcare Companies: Owlet (NYSE: OWLT), Phreesia (NYSE: PHR) and TriSalus Life Sciences (NASDAQ: TLSI)

Sean Dodge

BMO Capital

$14

Buy

-50.88%

Downside

Reiterated

06/22/26

Analysts Conflicted on These Healthcare Names: Phreesia (NYSE: PHR) and Novo Nordisk (NYSE: NVO)

Glen Santangelo

Barclays

$10

Hold

-64.91%

Downside

Reiterated

06/15/26

Barclays Sticks to Their Hold Rating for Phreesia (PHR)

Jailendra Singh

Truist Financial

―

Hold

―

Reiterated

06/12/26

Analysts Offer Insights on Healthcare Companies: Aethlon Medical (NASDAQ: AEMD), Johnson & Johnson (NYSE: JNJ) and Phreesia (NYSE: PHR)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$20

Buy

-29.82%

Downside

Reiterated

05/28/26

Jefferies Reaffirms Their Buy Rating on Phreesia (PHR)

Clark Wright

D.A. Davidson

$14

Buy

-50.88%

Downside

Reiterated

05/28/26

Analysts Offer Insights on Healthcare Companies: Phreesia (NYSE: PHR), M3 (Other OTC: MTHRF) and Eisai Co (Other OTC: ESALF)

Ryan Daniels

William Blair

―

Buy

―

Reiterated

05/28/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Phreesia (NYSE: PHR), Agilent (NYSE: A) and Pfizer (NYSE: PFE)

Daniel Grosslight

Citi

$10→$12

Hold

-57.89%

Downside

Reiterated

05/28/26

Phreesia price target raised to $12 from $10 at CitiPhreesia price target raised to $12 from $10 at Citi

Stan Berenshteyn

Wells Fargo

Hold

-68.42%

Downside

Reiterated

05/28/26

Analysts Offer Insights on Healthcare Companies: Phreesia (NYSE: PHR), McKesson (NYSE: MCK) and Biohaven Ltd. (NYSE: BHVN)

Jessica Tassan

Piper Sandler

$23→$12

Hold

-57.89%

Downside

Downgraded

05/28/26

Phreesia downgraded to Neutral from Overweight at Piper SandlerPhreesia downgraded to Neutral from Overweight at Piper Sandler

Ryan MacDonald

Needham

$14

Buy

-50.88%

Downside

Reiterated

05/28/26

Analysts Are Bullish on Top Healthcare Stocks: Phreesia (PHR), CSPC Pharmaceutical Group (CHJTF)

Ryan Halsted

RBC Capital

$19

Buy

-33.33%

Downside

Reiterated

05/27/26

RBC Capital Remains a Buy on Phreesia (PHR)

Scott Schoenhaus

KeyBanc

$15→$12

Buy

-57.89%

Downside

Assigned

04/13/26

Phreesia (PHR) Gets a Buy from KeyBanc

Aaron Kimson

Citizens JMP

―

Hold

―

Downgraded

04/01/26

Phreesia downgraded to Market Perform from Outperform at CitizensPhreesia downgraded to Market Perform from Outperform at Citizens

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Phreesia

3 Months

John RansomRaymond James

Success Rate

9/16 ratings generated profit

Average Return

+0.33%

Copying John Ransom's trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +0.33% per trade.

1 Year

Ryan DanielsWilliam Blair

Success Rate

4/9 ratings generated profit

Average Return

-14.94%

Copying Ryan Daniels's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -14.94% per trade.

2 Years

Ryan DanielsWilliam Blair

Success Rate

4/9 ratings generated profit

Average Return

+1.37%

Copying Ryan Daniels's trades and holding each position for 2 Years would result in 44.44% of your transactions generating a profit, with an average return of +1.37% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0A23 Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0A23 has received 2 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 0A23 average Analyst price target in the past 3 months is 13.50.

Each month's total comprises the sum of three months' worth of ratings.

0A23 Financial Forecast

0A23 Earnings Forecast

Next quarter’s earnings estimate for 0A23 is $0.09 with a range of $0.01 to $0.19. The previous quarter’s EPS was $0.05. 0A23 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0A23 has Performed in-line its overall industry.

0A23 Sales Forecast

Next quarter’s sales forecast for 0A23 is $129.06M with a range of $127.00M to $130.92M. The previous quarter’s sales results were $130.94M. 0A23 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0A23 has Performed in-line its overall industry.

0A23 Stock Forecast FAQ

What is GB:0A23’s average 12-month price target, according to analysts?

Based on analyst ratings, Phreesia’s 12-month average price target is 13.50.

What is GB:0A23’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for GB:0A23, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Phreesia a Buy, Sell or Hold?

Phreesia has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 3 hold ratings and 0 sell ratings.

What is Phreesia’s share price target?

The average share price target for Phreesia is 13.50. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $16.00 ,and the lowest forecast is $10.00. The average share price target represents -52.63% Decrease from the current price of $28.5.

What do analysts say about Phreesia?

Phreesia’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Phreesia?

To buy shares of GB:0A23, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Phreesia (0A23) Share Forecast & Price Target

0A23 Analyst Ratings

0A23 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Phreesia

0A23 Analyst Recommendation Trends

0A23 Financial Forecast

0A23 Earnings Forecast

0A23 Sales Forecast

0A23 Stock Forecast FAQ

Detailed List of Analyst Forecasts